Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed Reports 2023 Financial Results and Operational Progress

GlobeNewswire March 28, 2024

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

GlobeNewswire March 21, 2024

Affimed Announces 1-for-10 Reverse Stock Split

GlobeNewswire March 6, 2024

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

GlobeNewswire January 8, 2024

Affimed Announces Leadership Change and Organizational Restructuring

GlobeNewswire January 8, 2024

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

GlobeNewswire January 3, 2024

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

GlobeNewswire December 11, 2023

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

GlobeNewswire December 11, 2023

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

GlobeNewswire December 4, 2023

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

GlobeNewswire November 14, 2023

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

GlobeNewswire November 9, 2023

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

GlobeNewswire November 7, 2023

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire November 3, 2023

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

GlobeNewswire November 2, 2023

Affimed to Participate in Upcoming Investor Conferences

GlobeNewswire November 1, 2023

Affimed Announces Listing Transfer to Nasdaq Capital Markets

GlobeNewswire October 4, 2023

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire September 27, 2023

Affimed to Present at the Cantor Global Healthcare Conference 2023

GlobeNewswire September 21, 2023

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

GlobeNewswire September 12, 2023

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire September 7, 2023